Completed OBSERVATIONAL NCT00195286

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Urinary Infections

Interventions piperacillin/tazobactam

Updated 7 times since 2017 Last updated: Sep 24, 2009 Started: Jun 30, 2004 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Urinary Infections, this trial is completed. The trial is conducted by Wyeth is now a wholly owned subsidiary of Pfizer and has accumulated 7 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antequera (Málaga), Spain , Barcelona, Spain , Berga (Barcelona), Spain , Cadiz, Spain , Castellon, Spain , Ciudad Real, Spain , Cuenca, Spain , Cáceres, Spain , Ferrol, Spain , Granada, Spain and 17 more locations